| Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia HLM Koskela, S Eldfors, P Ellonen, AJ van Adrichem, H Kuusanmäki, ... New England Journal of Medicine 366 (20), 1905-1913, 2012 | 851 | 2012 |
| Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia HLM Rajala, S Eldfors, H Kuusanmäki, AJ Van Adrichem, T Olson, ... Blood, The Journal of the American Society of Hematology 121 (22), 4541-4550, 2013 | 324 | 2013 |
| Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3 EM Haapaniemi, M Kaustio, HLM Rajala, AJ van Adrichem, L Kainulainen, ... Blood, The Journal of the American Society of Hematology 125 (4), 639-648, 2015 | 292 | 2015 |
| Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020 | 133 | 2020 |
| Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target O Dufva, M Kankainen, T Kelkka, N Sekiguchi, SA Awad, S Eldfors, ... Nature communications 9 (1), 1567, 2018 | 129 | 2018 |
| Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, EI Andersson, ... Leukemia 28 (8), 1738-1742, 2014 | 126 | 2014 |
| Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia E Andersson, H Kuusanmäki, S Bortoluzzi, S Lagström, A Parsons, ... Leukemia 30 (5), 1204-1208, 2016 | 90 | 2016 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer discovery 12 (2), 388-401, 2022 | 86 | 2022 |
| Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia S Eldfors, H Kuusanmäki, M Kontro, MM Majumder, A Parsons, H Edgren, ... Leukemia 31 (1), 51-57, 2017 | 52 | 2017 |
| Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing MM Majumder, R Silvennoinen, P Anttila, D Tamborero, S Eldfors, ... Oncotarget 8 (34), 56338, 2017 | 44 | 2017 |
| Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ... Blood 141 (13), 1610-1625, 2023 | 35 | 2023 |
| Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing PO Pietarinen, T Pemovska, M Kontro, B Yadav, JP Mpindi, EI Andersson, ... Blood cancer journal 5 (5), e309-e309, 2015 | 35 | 2015 |
| In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen, ... Blood cancer journal 7 (9), e604-e604, 2017 | 32 | 2017 |
| Patient-tailored design for selective co-inhibition of leukemic cell subpopulations A Ianevski, J Lahtela, KK Javarappa, P Sergeev, BR Ghimire, P Gautam, ... Science advances 7 (8), eabe4038, 2021 | 30 | 2021 |
| Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling H Kuusanmäki, O Dufva, E Parri, AJ van Adrichem, H Rajala, ... Oncotarget 8 (57), 97516, 2017 | 30 | 2017 |
| Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia BS White, SA Khan, MJ Mason, M Ammad-Ud-Din, S Potdar, D Malani, ... NPJ precision oncology 5 (1), 71, 2021 | 23 | 2021 |
| Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia H Kuusanmäki, S Kytölä, I Vänttinen, T Ruokoranta, A Ranta, ... Haematologica 108 (7), 1768, 2023 | 20 | 2023 |
| Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors PO Pietarinen, CA Eide, P Ayuda-Durán, S Potdar, H Kuusanmäki, ... Oncotarget 8 (14), 22606, 2017 | 19 | 2017 |
| Endogenous and combination retinoids are active in myelomonocytic leukemias O Di Martino, H Niu, G Hadwiger, H Kuusanmaki, MA Ferris, A Vu, ... haematologica 106 (4), 1008, 2021 | 18 | 2021 |
| Identification of novel regulators of STAT3 activity E Parri, H Kuusanmäki, AJ van Adrichem, M Kaustio, K Wennerberg PloS one 15 (3), e0230819, 2020 | 17 | 2020 |
